Engflag

Serax D

Quick links to important sections

Serax D

Serax D_PL

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Serax D

Quick Facts

Property Description
Active ingredient Diclofenac Potassium, Serratiopeptidase
Form Fixed-Dose Combination (FDC) Tablet, Oral formulation
Pharmacological class Non-Steroidal Anti-Inflammatory Drug (NSAID) and Systemic Proteolytic Enzyme
Common use Relief of pain, inflammation, and associated swelling
Origin Synthetic (Diclofenac), Enzymatic (Serratiopeptidase)

What Type of Medicine is Serax D?

Serax D is categorized as a fixed-dose combination (FDC) medicinal product, which means it is an oral formulation (a tablet) that integrates two distinct active ingredients into one dose. This combination establishes its identity as belonging to two separate pharmacological classes: a Non-Steroidal Anti-Inflammatory Drug (NSAID) and a Systemic Proteolytic Enzyme. This specific dual-action type of medication is clinically recognized for its role in enhancing the anti-inflammatory effect by combining two different therapeutic mechanisms.

Composition and Active Ingredients: Diclofenac and Serratiopeptidase

The composition of the drug relies on the two core substances: Diclofenac Potassium and Serratiopeptidase. Diclofenac Potassium is a synthetic compound classified as an NSAID, an established agent known for its analgesic and anti-inflammatory activity. Serratiopeptidase is an enzymatic substance that functions as a proteolytic enzyme, distinguishing the formulation by its focus on breaking down inflammatory proteins. This combination formulation is a common market strategy to address both the pain-signaling and the physical swelling components of inflammation simultaneously.

General Purpose: Dual Action Against Pain and Swelling

The general purpose of Serax D is to provide comprehensive relief from physical discomfort by employing a dual action against pain and inflammation. The Diclofenac Potassium component works to suppress the chemical signaling that initiates pain and swelling, while the Serratiopeptidase component aids in the breakdown and clearance of accumulated inflammatory matter, helping to resolve associated swelling (edema). A typical neutral use scenario for this FDC includes addressing the discomfort and swelling that follow minor injuries or dental procedures. This strategy aims to efficiently address both the immediate discomfort and the underlying inflammatory process.

What side effects are possible with Serax D?

Serax D is a combination medicine containing an NSAID (diclofenac) and an opioid (codeine). Its safety profile reflects the risks associated with both classes of drugs, necessitating specific patient monitoring and restrictions.

Serious Safety Warnings

Cardiovascular Risks: Diclofenac is associated with a small increased risk of serious arterial thrombotic events, including myocardial infarction (heart attack) and stroke, which can be fatal. This risk may increase with higher doses and long-term use. The medication is contraindicated in patients with established congestive heart failure (NYHA class II–IV), ischemic heart disease, peripheral arterial disease, or cerebrovascular disease.

Gastrointestinal Risks: NSAIDs cause a risk of serious gastrointestinal adverse events, such as bleeding, ulceration, and perforation of the stomach or intestines, which can occur without warning symptoms and may be fatal. This risk is higher in older adults and those with a history of GI disease.

Respiratory Depression (Codeine): As an opioid, codeine carries a risk of serious, life-threatening respiratory depression. This is particularly concerning when used in individuals who are ultra-rapid metabolizers of codeine, in children after tonsillectomy/adenoidectomy, and in conjunction with other central nervous system depressants, including alcohol.

Common and Other Adverse Reactions

Common side effects primarily affect the gastrointestinal system and central nervous system. These may include nausea, vomiting, stomach pain, indigestion, diarrhea, dizziness, headache, and drowsiness.

Population and Dose-Specific Restrictions

  • Pregnancy: Use is generally avoided during the third trimester due to the risk of premature closure of the fetal ductus arteriosus. Use during breastfeeding is not recommended due to the potential for serious adverse effects in the infant from codeine exposure.
  • Pediatric Use: Codeine is not recommended for pain relief in children under 12 years of age or in adolescents between 12 and 18 years with certain breathing problems.
  • Hepatic/Renal Impairment: Caution and close monitoring of function are required, as the components can affect the kidneys and liver. The lowest effective dose for the shortest duration possible should always be used to minimize potential risks, especially cardiovascular and GI events.

Overdose and Emergency Response

The overdose profile for Serax D is primarily determined by the severe systemic risks associated with its Diclofenac Potassium component, as documented in regulatory sources. Initial manifestations commonly include nausea, vomiting, stomach pain, and lethargy.

Official regulatory information lists severe, life-threatening outcomes affecting multiple physiological systems. These serious manifestations may include severe gastrointestinal bleeding and perforation, central nervous system effects such as convulsions and coma, cardiovascular events like arrhythmia or severe hypotension, and acute damage to the kidneys (renal failure) and liver. Patients with pre-existing hepatic or renal impairment are noted to be at an increased risk of severe complications.

In the event of a suspected overdose, immediate medical attention must be sought. Official guidance mandates contacting a poison control center or emergency services right away. No specific antidote is known for this overdose. Management consists of providing symptomatic and supportive care, which may involve the administration of activated charcoal in appropriate cases following a recent, large ingestion, as defined by medical protocols.

Therapeutic Uses of Serax D

Quick Facts: Uses of Serax D

  • Relief from Pain: Utilized for temporary relief of discomfort in certain musculoskeletal and inflammatory conditions.
  • Reduction of Inflammation: May be considered in the management of swelling and redness associated with injury.
  • Arthritic Conditions: Supports comfort for individuals with certain forms of arthritis.

Serax D is an oral medication that may be indicated for the short-term relief of pain and inflammation associated with a range of conditions. Its primary role involves the support of comfort for individuals experiencing pain from musculoskeletal or soft tissue injuries, such as sprains and strains. The medication is also utilized in the management of discomfort linked to certain rheumatic diseases, including rheumatoid arthritis and osteoarthritis.

Additionally, Serax D may be prescribed to address post-operative discomfort and inflammation following surgical procedures, contributing to the management of swelling. When used as directed by a healthcare professional, the medicine can be part of a regimen to help manage symptoms of pain in conditions like ankylosing spondylitis and various forms of headache. It is important to note that Serax D is a combination product used to help with these physical manifestations.

Eligibility and Restrictions for Use

Serax D (Diclofenac Potassium/Serratiopeptidase) eligibility is primarily defined by official regulatory guidelines that impose absolute restrictions based on certain pre-existing conditions and physiological states. Use is generally established for Adults who do not have any documented contraindications. Eligibility criteria are often strictly aligned with the restrictions for its NSAID component, Diclofenac.

Populations Who Must Not Use Serax D (Contraindications)

Eligibility Restriction Condition
Allergy Known hypersensitivity to the active ingredients, Aspirin, or any NSAID drug.
Gastrointestinal Active or history of recurrent peptic ulcer, GI bleeding, or perforation.
Cardiovascular Established severe heart failure (NYHA II–IV), ischemic heart disease, or post-CABG surgery.
Organ Function Severe hepatic failure or severe renal failure.
Pregnancy Women in the last trimester (from 30 weeks gestation).

Conditional or Restricted Use

Use is generally Not Recommended in children and adolescents under 18 years of age as safety and efficacy are not fully established for this age group. Older adults require restricted use with medical supervision due to an increased risk of serious events. Use is conditional for patients with non-severe hepatic or renal impairment and those with a history of gastrointestinal disease or asthma. The medicine is also not recommended for women who are breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Serax D (Oxazepam) interacts with certain medicines and substances, primarily due to additive effects on the central nervous system (CNS) and potential interference with its clearance pathway.

Clinically Significant Interactions

Interacting Product Category Nature of Interaction Implication (Official Warning)
Opioids Additive CNS Depression Increases risk of profound sedation, respiratory depression, coma, and death; reserve for use when alternatives are inadequate.
Other CNS Depressants (e.g., alcohol, sedatives, antidepressants, antipsychotics) Additive CNS Depression Potentiated sedation and impaired motor function; concomitant use requires caution or avoidance.
Flumazenil (Benzodiazepine Antagonist) Precipitates Withdrawal Use to reverse Oxazepam effects may induce acute withdrawal symptoms, including seizures.

Altered Drug Levels

Oxazepam is primarily cleared from the body via glucuronidation, a metabolic process generally less affected by liver function than other pathways. However, substances that influence this process may alter Oxazepam exposure.

  • Increased Levels: Drugs that inhibit UGT enzymes (the enzymes responsible for glucuronidation), such as Probenecid, may reduce Oxazepam clearance, potentially increasing its effects.
  • Decreased Levels: Substances that induce metabolism, such as Rifampicin or Oestrogen-containing oral contraceptives, may lead to decreased Oxazepam plasma levels, potentially reducing its efficacy.

Other Substance Interactions

Alcohol is not recommended for concomitant use as it significantly enhances the sedative effects of Oxazepam. Additionally, use in geriatric or debilitated patients may require dosage adjustment due to increased susceptibility to interaction-related CNS depression.

Mechanism of Action

How Serax D Works

Serax D is a combination product where each component exerts its effects through distinct mechanistic domains to modify specific physiological pathways.

Modulation of Inflammatory Mediators

The first component, Diclofenac, operates within domains involving enzyme-mediated signaling. It functions as an inhibitor of the cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. This interaction suppresses the biosynthesis of prostaglandins, which are localized lipid mediators involved in cellular signaling. The resulting suppression of prostaglandin generation leads to predictable pathway adjustments in processes regulated by these mediators.

Proteolytic Breakdown of Abnormal Proteins

This mechanistic domain is governed by the second component, Serratiopeptidase, a proteolytic enzyme. It engages mechanisms that modify biological processes by catalyzing the selective breakdown of insoluble protein by-products, such as fibrin, that accumulate within specific extracellular matrices. This enzymatic action alters the structural composition of these biological matrices and modifies the viscosity of certain biological fluids, thereby influencing the localized tissue environment.

Dosage and Administration Information

How Serax D is Used

Serax D is administered through the oral route as a fixed-dose combination tablet. The tablet must be swallowed whole with a full glass of water and must not be crushed or chewed to preserve the intended release profile of the components. The proper use of the medication is governed by the principles of the NSAID component, Diclofenac.

Dosing and Frequency

The dosage is based on the 50 mg Diclofenac Potassium strength per tablet. Standard usage involves taking the medicine in divided doses, typically two or three times daily, to ensure a consistent therapeutic level. It is generally advised to take the tablet with or immediately after food to help minimize potential gastrointestinal discomfort. The maximum daily intake of Diclofenac should not exceed 150 mg in adults.

Duration and Special Use Considerations

The usage of Serax D is restricted to the shortest possible duration necessary for symptomatic control, aligning with its role in short-term symptomatic treatment. If a dose is missed, it should be skipped, and the regular schedule continued; doubling the dose is prohibited. For older adults, it is recommended to use the lowest effective dose for the shortest duration. Cautionary dose adjustment may also be required for patients with impaired renal or hepatic function.

Recent Clinical Evidence

Research evidence / Overview of studies for Serax D

Evidence for Use in Post-operative Pain and Swelling

Research examined the fixed-dose combination of Serax D in clinical contexts characterized by heightened symptom activity following surgical and dental procedures. Short-term Randomized Controlled Trials (RCTs) and comparative studies were used in research exploring how symptoms change over time. Studies monitored measurements of outcomes related to physical discomfort, specifically assessing changes in pain intensity and the reduction of physical swelling (edema) in the affected area.

The studies report how symptoms evolved in the observed populations over a very short-term follow-up duration, usually less than one week. Findings describe patterns observed in the studies in measurements of outcomes related to physical discomfort and swelling. Comparative evidence has been explored, and findings varied across studies regarding the difference in measured outcomes when the combination was compared to Diclofenac alone.

Evidence for Use in Osteoarthritis and Joint Comfort

The combination drug was studied for outcomes related to physical discomfort and functional imbalance for conditions like knee osteoarthritis (OA). These studies primarily took the form of comparative trials that assessed adult patients diagnosed with OA of the knee over short defined time intervals. Findings were mixed across the research for the combination drug regarding whether the addition of Serratiopeptidase to Diclofenac was associated with different measured outcomes compared to Diclofenac alone.

What is Still Uncertain About the Research for Serax D

A primary research gap is the limited follow-up durations, meaning little is known about long-term outcomes. Furthermore, the comparative evidence is lacking from large-scale studies designed to definitively address the clinical difference between taking the combination drug and taking Diclofenac monotherapy. The evidence quality varies across studies, particularly for the Serratiopeptidase component, and the modest sample sizes in some FDC trials mean the research highlights what is known but also what is still uncertain about the generalizability of the findings.

Key Studies & References Randomized Controlled Trial Investigating FDC Use in Osteoarthritis of the Knee Joint

Frequently Asked Questions (FAQ)

Common questions about Serax D (FAQ)

Q: Does Serax D contain an antihistamine?

Yes, official product information confirms that Serax D contains an antihistamine component. Specifically, it includes dexchlorpheniramine maleate, which is a type of antihistamine used to relieve allergy symptoms.

Q: What is the intended use of Serax D?

Regulatory documents indicate that Serax D is used for the temporary relief of symptoms associated with seasonal and perennial allergic rhinitis, such as nasal congestion, sneezing, runny nose, and itchy, watery eyes. Its formulation includes both an antihistamine and a decongestant, according to regulatory documents.

Q: Can I take Serax D if I have high blood pressure?

According to the official product information, Serax D should be used with caution, or is contraindicated, in patients with high blood pressure (hypertension). The decongestant component may potentially affect blood pressure. Regulatory labeling consistently recommends discussing pre-existing conditions, like hypertension, with a healthcare professional.

Q: Does Serax D cause drowsiness or affect my ability to drive?

Official information for Serax D warns that it may cause drowsiness, sleepiness, or dizziness, which could impair the ability to drive or operate machinery. Official information indicates that caution is necessary and individuals should understand how the medication affects them before performing tasks requiring mental alertness.

Q: Can Serax D be used by children?

The official regulatory documents state that Serax D is not recommended for use in children under the age of 12 years. Dosing and safety profiles have been established for older individuals. Information regarding appropriate pediatric alternatives is typically obtained from a healthcare provider.

Q: What is the active decongestant ingredient in Serax D?

Serax D contains pseudoephedrine sulfate as its active decongestant ingredient. This component is known to help narrow blood vessels in the nasal passages, supporting the reduction of swelling and congestion, according to official information.

Q: Can I drink alcohol while taking Serax D?

According to the official product labeling, using alcohol while taking Serax D is advised against. The combination can increase the sedative effects, such as drowsiness and dizziness, caused by the antihistamine component in the medication.

How should Serax D be stored and disposed of?

How to Store and Dispose of Serax D

Official regulatory documents define strict storage and disposal requirements for Serax D (Diclofenac Potassium and Serratiopeptidase) tablets to maintain product quality and environmental safety.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, specifically 15 C to 30 C (59 F to 86 F).
Protection Keep in the original, tightly closed container, shielded from moisture and direct sunlight.
Safety Must be kept out of the reach of children and pets.

Disposal Instructions

Disposal instructions prohibit discarding the tablets into the toilet or drainage system. Unused or expired medicine must be disposed of through authorized pharmaceutical take-back programs or by following local, regional, and national hazardous waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Serax D found in:

A-Z Index: